Compare COVID-19 Oral Antivirals

You'll be asked about the new COVID-19 oral antivirals nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.

Eligibility. Educate that these meds are for outpatients with a positive COVID-19 test who are at high risk of developing severe illness (diabetes, etc)...regardless of vaccination status.

Nirmatrelvir/ritonavir is for age 12 and up...molnupiravir is for 18 and up. Either is started within 5 days of symptoms...and used bid for 5 days. Patients don't currently have to pay for them.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote